Kim Branson, SVP and Global Head of AI and Machine Learning for GSK, discusses how AI has revolutionized drug discovery and development, highlighting its applications in the lab. They also delve into the criteria for an ideal biopharma partner and the allure of innovative solutions in the biotech AI space.
AI has revolutionized drug discovery through advanced measurement technologies and machine learning.
Pharmaceutical companies are evolving into immune programming entities, leveraging AI software for accurate patient response predictions.
Deep dives
AI's Impact on Drug Discovery and Development
AI has significantly improved drug discovery by utilizing cheap and advanced measurement technologies like sequencing and RNA-seq. With the increasing amount of data, machine learning has become essential in analyzing and making sense of this information. The podcast discusses how AI can be deployed in the lab to enhance drug discovery processes, highlighting the vital role of new measurement technologies and machine learning in advancing medicine.
Importance of Structured Biology and Computational Methods
Kim Branson, the guest in the podcast, shares his journey from a math-physics-oriented background to diving into molecular biology and bacterial pathogenesis during university. He emphasizes the allure of structured biology and computational methods in understanding complex biological systems. Branson's experience in computational tools for drug design dates back to his involvement in designing drugs using computational methods like Goodford's Grid. This showcases how computational methods have evolved over the years, contributing to advancements in drug development.
Future of AI Integration in Healthcare and Pharma
The podcast delves into the potential future landscape of healthcare and pharmaceuticals, envisioning AI software integrated with every drug launched by companies like GSK. The emphasis is on leveraging software to identify appropriate users and predict patient responses accurately. The discussion highlights the transformation of pharmaceutical companies like GSK into immune programming entities, focusing on vaccines as tools for immune system programming and future advancements in immunotherapy and autoimmune disease treatments.
Challenge of Generating Data with Outcomes for Advancing Research
The rate-limiting step in advancing drug discovery lies in acquiring data with outcomes, particularly in clinical trial settings. While data is crucial, having linked outcomes to the data becomes paramount for understanding treatment impacts. The discussion centers around establishing large-scale observational cohorts to capture data not limited to genetic sequencing and electronic medical records but extending to following individuals over time to track immune system evolution and treatment outcomes.
Kim Branson, PhD, SVP and Global Head of AI and Machine Learning for GSK, joins Vijay Pande, founding partner at a16z Bio + Health.
Together, they talk about how AI has improved drug discovery and development, as Kim walks through all the ways AI can be deployed in the lab. They also get into detail about what an ideal partner looks like and what kind of solution is attractive to a big biopharma, making this a particularly relevant episode for builders in biotech AI.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode